Susan Foden

Susan Elizabeth Foden formerly worked at Cancer Research Ventures Ltd., as Chief Executive Officer from 1998 to 2000, Cancer Research Technology Ltd., as Chief Executive Officer in 2000, The Cancer Research Campaign, as Chief Executive Officer in 2000, Cancer Research Campaign Technology Ltd., as Chief Executive Officer from 1987 to 2000, BerGenBio ASA, as Non-Executive Chairman from 2013 to 2014, Neurocentrx Pharma Ltd., as Chairman, TheraCryf Plc, as Chairman from 2023 to 2024, The UK Innovation & Science Seed Fund LP, as Chairman, Qbiotics Group Ltd., as Chairman, Piramed Ltd., as Director, Vectura Group Ltd., as Independent Non-Executive Director from 2010 to 2016, BTG Ltd., as Independent Non-Executive Director, Source BioScience Ltd., as Senior Independent Non-Executive Director from 2012 to 2015, Excalibur Fund Managers Ltd., as Investor Director from 2000 to 2003, Innovata Ltd., as Non-Executive Director, Lifearc, as Non-Executive Director, Elara Pharmaceuticals GmbH, as Director-Supervisory Board, Cizzle Biotechnology Ltd., as Non-Executive Director, Evgen Ltd., as Non-Executive Director from 2011 to 2015, Oxford Ancestors Ltd., as Non-Executive Director, Cell Therapy Catapult Ltd., as Non-Executive Director, Vectura Ltd., as Director, Spectrum Ltd., as Non-Executive Director, Cascade Fund Management Ltd., as Non-Executive Director, Vectura GmbH, as Director, Butterfly Conservation, as Director, Cascade Ltd., as Non-Executive Director, Newlands Court Management Co. Ltd., as Director, Laverock Therapeutics Ltd., as Non-Executive Director, The Institute of Cancer Research: Royal Cancer Hospital, as Trustee, Celltech Ltd., as Head-Academic Liaison, Celltech Group Ltd., as Head-Academic Liaison, and ROSLIN FOUNDATION, as Trustee.
Dr. Foden received her graduate degree and doctorate degree from the University of Oxford.